van Steenoven, Inger http://orcid.org/0000-0002-9801-2848
van der Flier, Wiesje M.
Scheltens, Philip
Teunissen, Charlotte E.
Lemstra, Afina W.
Funding for this research was provided by:
ZonMw (733050509)
Article History
Received: 22 March 2019
Accepted: 9 September 2019
First Online: 10 October 2019
Ethics approval and consent to participate
: The study was approved by the local Medical Ethical Committee. All patients provided written informed consent for their clinical data and CSF to be used for research purposes.
: Not applicable.
: Wiesje M van der Flier performs contract research for Boehringer Ingelheim. Research programs of Wiesje M. van der Flier have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, and Janssen Stellar. All funding is paid to her institution. Philip Scheltens has served as a consultant for Wyeth-Elan, Genentech, Danone, and Novartis and received funding for travel from Pfizer, Elan, Janssen, and Danone Research. Charlotte E. Teunissen is a member of the Innogenetics International Advisory Boards of Fujirebio/Innogenetics and Roche. Inger van Steenoven and Afina W. Lemstra declare that they have no competing interests.